About Keratin, type I cytoskeletal 17
Keratin, type I cytoskeletal 17 (KRT17) is a protein
from Homo sapiens identified by UniProt accession
Q04695, 432 residues long.
MolForge cross-references it against 0 known binders and
449 disease associations.
Target properties
| Protein name | Keratin, type I cytoskeletal 17 |
| UniProt accession | Q04695 |
| Gene | KRT17 |
| Organism | Homo sapiens |
| Length | 432 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (449)
Diseases linked to this target (Open Targets).
- pachyonychia congenita 2 · score 0.80
- sebocystomatosis · score 0.78
- pachyonychia congenita · score 0.39
- Anonychia · score 0.34
- Abnormality of the skin · score 0.34
- clear cell renal carcinoma · score 0.18
- glioblastoma multiforme · score 0.18
- genetic disorder · score 0.18
- breast adenocarcinoma · score 0.18
- esophageal cancer · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q04695-F1 | alphafold | PREDICTED | 77.33 | — |
Amino-acid sequence (432 residues)
MTTSIRQFTS SSSIKGSSGL GGGSSRTSCR LSGGLGAGSC RLGSAGGLGS TLGGSSYSSC YSFGSGGGYG SSFGGVDGLL AGGEKATMQN LNDRLASYLD KVRALEEANT ELEVKIRDWY QRQAPGPARD YSQYYRTIEE LQNKILTATV DNANILLQID NARLAADDFR TKFETEQALR LSVEADINGL RRVLDELTLA RADLEMQIEN LKEELAYLKK NHEEEMNALR GQVGGEINVE MDAAPGVDLS RILNEMRDQY EKMAEKNRKD AEDWFFSKTE ELNREVATNS ELVQSGKSEI SELRRTMQAL EIELQSQLSM KASLEGNLAE TENRYCVQLS QIQGLIGSVE EQLAQLRCEM EQQNQEYKIL LDVKTRLEQE IATYRRLLEG EDAHLTQYKK EPVTTRQVRT IVEEVQDGKV ISSREQVHQT TR
Explore Keratin, type I cytoskeletal 17 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets